(Q33333854)

English

Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1 reference

based on heuristic

inferred from title

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Chen Y

1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Perng RP

2

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Yang KY

3

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Lin WC

4

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Wu HW

5

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Tsai CM

6

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Whang-Peng J

7

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

publication date

1 August 2000

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

139-146

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Drugs ten years later: epirubicin.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of ifosfamide plus high-dose epirubicin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. A biologically important observation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen aziridine, a novel affinity probe for P-glycoprotein in multidrug resistant cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen decreases drug efflux from liposomes: relevance to its ability to reverse multidrug resistance in cancer cells?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of ifosfamide and etoposide chemotherapy for extensive-disease small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900106-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0169-5002(00)00106-9

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33333854&oldid=1962138009"